Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients

Axel Haverich, Stanton K. Shernan, Jerrold H. Levy, John C. Chen, Michel Carrier, Kenneth M. Taylor, Frans Van de Werf, Mark F. Newman, Peter X. Adams, Thomas G. Todaro, Michael van der Laan, Edward D. Verrier

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Background: Morbidity and mortality after coronary artery bypass graft surgery are directly related to specific preoperative risk factors. We assessed the influence of preoperative risk factors on the effect of pexelizumab, a C5 complement inhibitor, to reduce postoperative morbidity and mortality in this post hoc analysis of the Pexelizumab for Reduction in Myocardial Infarction and MOrtality in Coronary Artery Bypass Graft surgery (PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Methods: The composite endpoint of death or myocardial infarction or both through postoperative day 30 was examined in subpopulations of patients with pre-specified risk factors, which included diabetes mellitus, prior coronary artery bypass graft, urgent intervention, female sex, history of neurologic event, history of congestive heart failure, and two or more previous myocardial infarctions or a recent myocardial infarction. Stratified post hoc analyses were also performed on patients presenting with two or more and three or more of those risk factors. Results: Pexelizumab significantly reduced the incidence of the composite endpoint of death or myocardial infarction through postoperative day 30 by 28% in patients with two or more risk factors (p = 0.004) and 44% in patients with three or more risk factors (p < 0.001). Conclusions: The C5 complement inhibitor, pexelizumab, reduced morbidity and mortality among high-risk patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Original languageEnglish
Pages (from-to)486-492
Number of pages7
JournalAnnals of Thoracic Surgery
Volume82
Issue number2
DOIs
StatePublished - Aug 2006

Bibliographical note

Funding Information:
Funding for the PRIMO-CABG study was provided by the study’s joint sponsors, Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Alexion Pharmaceuticals, Cheshire, Connecticut. Data for the current manuscript were provided by the sponsors to the authors at their request for their independent analysis and interpretation.

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients'. Together they form a unique fingerprint.

Cite this